Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9805561 | 0.86 | NPC1 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL622260 | 0.80 | GBA1 (0.41) | GBA1ALDH1A1KDM4ENPC1TSHR | |
| SCHEMBL29600434 | 0.80 | GBA1 (0.41) | GBA1ALDH1A1KDM4ENPC1TSHR | |
| SCHEMBL31212506 | 0.77 | CA12 (0.37) | ADRA2AADRA2BADRA2C | |
| SCHEMBL22151010 | 0.77 | CA12 (0.37) | ADRA2AADRA2BADRA2C | |
| SCHEMBL13680819 | 0.77 | DAO (0.46) | ALDH1A1MBOAT4 | |
| SCHEMBL6197859 | 0.77 | CCR1 (0.40) | ALDH1A1KDM4ENPC1ADRA2AADRA2B | |
| SCHEMBL13680812 | 0.77 | ESR1 (0.42) | — | |
| SCHEMBL13680816 | 0.77 | DAO (0.35) | ALDH1A1KDM4ETSHRADRA2AADRA2B | |
| SCHEMBL27689054 | 0.77 | GBA1 (0.36) | GBA1ALDH1A1KDM4ENPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491035-B1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9161934-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8962652-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8507507-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| CN-102666541-A | Purine or deazapurine derivatives for the treatment of, in particular, viral infections | GILEAD SCIENCES INC | 2012-09-12 | — | — | CN | disclosed |
| EP-2491035-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2011049825-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-5808101-A | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| US-5710288-A | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents | ALLERGAN (US) | 1998-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | GBA1 2706/4885ALDH1A1 2598/4885KDM4E 1889/4885 |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | GBA1 1082/4885ALDH1A1 963/4885KDM4E 3501/4885 |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | GBA1 1082/4885ALDH1A1 963/4885KDM4E 3501/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | GBA1 3373/4885ALDH1A1 4242/4885KDM4E 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.